ANNUAL REPORT 2008

The mandate of the Patented Medicine Prices Review Board is to ensure that prices charged by patentees patented medicines sold in Canada are not excessive; and, to report on pharmaceutical trends of all medicines and on R&D spending by pharmaceutical patentees.

Table Of Contents

1. HIGHLIGHTS 2008
2. CHAIRMAN'S MESSAGE
3. ABOUT THE PATENTED MEDICINE PRICES REVIEW BOARD: MANDATE AND JURISDICTION
4. GOVERNANCE
5. REGULATORY REPORTING REQUIREMENTS
6. VOLUNTARY COMPLIANCE UNDERTAKINGS
7. HEARINGS
8. MATTERS BEFORE THE FEDERAL COURT
9. AMENDMENTS TO THE PATENTED MEDICINES REGULATIONS
10. REVIEW OF THE BOARD'S EXCESSIVE PRICE GUIDELINES
11. REPORTING INFORMATION ON KEY PHARMACEUTICAL TRENDS
12. PRICE TRENDS
13. COMPARISON OF CANADIAN PRICES TO FOREIGN PRICES
14. MANUFACTURING TRENDS IN CANADA
15. ANALYSIS OF RESEARCH AND DEVELOPMENT EXPENDITURES
16. NATIONAL PRESCRIPTION DRUG UTILIZATION INFORMATION SYSTEM
17. COMMUNICATIONS
18. GLOSSARY
19. ANNEX 1
20. ANNEX 2
21. ANNEX 3
22. ANNEX 4

View Full Report